Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

March 16, 2026
Pharmidex is proud to be the Networking Sponsor at the Immuno-Oncology & Biomarker Summit in London. Over the next two days, the event provides an opportunity to discuss the latest advances in immuno-oncology, biomarker discovery, and precision medicine. If you’re attending, come and say hello to Ash Alavijeh to connect and explore opportunities to collaborate.
March 13, 2026
We’re excited to announce that Janette Dalay Robertson , Business Development Manager at Pharmidex , will be attending and exhibiting at the 10th RSC-BMCS Symposium on Mastering Medicinal Chemistry on Friday 13 March 2026 at Burlington House, London. Pharmidex is also proud to be sponsoring this fantastic event, which brings together leaders and innovators from across the medicinal chemistry community. If you’re attending, make sure to stop by and speak with Janette at the Pharmidex stand. She will be delighted to connect, discuss your research, and explore how Pharmidex can support your drug discovery and development programmes. 🤝 We look forward to meeting fellow scientists, collaborators, and partners at this exciting meeting.
March 9, 2026
We are pleased to share that Janette Dalay Robertson will be attending Cell & Gene Therapy 2026 taking place 9–10 March 2026 at Hinxton Hall Conference Centre, Cambridge. This event is a fantastic opportunity to connect with leaders across the cell and gene therapy ecosystem and Janette will be there representing Pharmidex and discussing how our scientific services support drug discovery and development. 🤝 Janette would be delighted to meet with fellow attendees to: • Explore new collaborations • Discuss upcoming research programs • Share how Pharmidex can support innovative therapeutic development If you are attending, feel free to reach out and arrange a meeting during the event. We look forward to engaging conversations and building new partnerships within the cell and gene therapy community!
More Posts